Home » Patents » EU Commission: unitary patent concerns; IP insurance and unitary SPCs

EU Commission: unitary patent concerns; IP insurance and unitary SPCs

Keltie LLP

K2 IP Limited

About IPcopy

IPcopy is an intellectual property related news site covering a wide variety of IP related news and issues. We will also take the odd lighthearted look at IP. Feel free to contact us via the details on the About Us page. Disclaimer: Unless stated otherwise, the contributors to IPcopy (the "IPcopy writers") are patent and trade mark attorneys or patent and trade mark assistants at Keltie LLP or are network attorneys at K2 IP Limited. Guest contributors will be identified. This news site is the personal site of the contributors and is not edited by the authors' employer in any way. From time to time however IPcopy may publish practice notes, legal updates and marketing news from Keltie LLP or K2 IP Limited. Any such posts will be clearly marked. This news site is for information purposes only. Information posted to this news site is not legal advice and should not be taken as such. If you require IP related legal advice please contact your legal representative.

IMG_8533-1The European Commission website provides something of a byzantine navigational challenge so IPcopy is extremely grateful to Martin Chatel for pointing us in the direction of the Commission staff working document “A Single Market Strategy for Europe – Analysis and Evidence” which discusses the unitary patent package.

The working document highlights (page 70) a Eurostat study that suggests SMEs are only responsible for around 17% of patent filings in Europe. The need for EU wide support for SMEs is flagged up but the document notes that the cost exposure for SMEs in respect of IP rights and litigation is significant, hits SMEs disproportionately and may act as a barrier to engaging with the patent system. The potentially high court fees and damages that SMEs could be exposed to within an action at the Unified Patent Court (UPC) are raised as a particular concern.

In order to address some of the above concerns the Commission suggests it will extend its efforts to help SMEs via a number of means including ensuring that COSME funds (Europe’s programme for small and medium-sized enterprises) will be used to help innovative European SMEs apply for EU IP titles including the unitary patent and facilitating the launch of a European commercial IP legal costs insurance market.

The reference to the insurance angle is an interesting one and the Commission document goes on to say that the potential IP litigation costs that SMEs may be exposed to can only be addressed by a functioning IP litigation insurance market. It is suggested that such a market has not grown so far due to the limited size of the market at national level. The implementation of the unitary patent however is seen as a trigger that could help such a market grow.

The working document also suggests that such insurance schemes could, in addition to providing comfort against legal costs, lead to more investment by financial institutions into start-ups and SMEs.

The working document also highlights a number of other concerns around the unitary patent system such as:

  • The absence of a unitary SPC title. SPCs are regarded as instrumental for industry sectors whose products are subject to regulated market authorizations;
  • what happens if a unitary patent request is rejected, the impact of national prior art and the possible acceptable conditions to convert such a unitary patent into a bundle of national patents;
  • double patenting issues between the unitary patent and national patents; and
  • possible issues stemming from the obligation to designate all participating Member States for the purpose of obtaining a unitary patent [this last point is, IPcopy believes, a reference to the “Malta problem“].

On the issue of SPCs, the working document suggests that the Commission is going to consider re-calibrating the SPC framework in Europe by looking at: a unitary SPC; targeted SPC manufacturing waivers for export purposes that could allow EU-based manufacturers of generic and biosimilar medicines to compete on equal footing with competitors from non-EU countries; and the scope of the patent “Bolar” exemption in the EU.

Mark Richardson 7 December 2015


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: